Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Urethane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urethane SCHEMBL27766653 | 0.89 | — | — | |
| Urethane SCHEMBL27525378 | 0.87 | ALOX15 (0.79) | ALOX15ALDH1A1LMNAHSD17B10CYP1A2 | |
| Urethane SCHEMBL154279 | 0.87 | ALOX15 (0.88) | ALOX15ALDH1A1LMNAHSD17B10CYP1A2 | |
| Urethane SCHEMBL40457 | 0.87 | ALOX15 (0.88) | ALOX15ALDH1A1LMNAHSD17B10CYP1A2 | |
| Urethane SCHEMBL9699831 | 0.87 | — | — | |
| Urethane SCHEMBL4556053 | 0.87 | ALOX15 (0.88) | ALOX15ALDH1A1LMNAHSD17B10CYP1A2 | |
| Urethane SCHEMBL367439 | 0.87 | ALOX15 (1.00) | ALOX15ALDH1A1LMNAHSD17B10CYP1A2 | |
| Urethane SCHEMBL8129017 | 0.87 | ALOX15 (1.00) | ALOX15ALDH1A1LMNAHSD17B10CYP1A2 | |
| Urethane SCHEMBL8830978 | 0.87 | ALOX15 (1.00) | ALOX15ALDH1A1LMNAHSD17B10CYP1A2 | |
| Urethane SCHEMBL8136 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070087047-A1 | Enhanced circulation effector composition and method | ALZA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-7160554-B2 | Enhanced circulation effector composition and method | ALZA CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7150882-B2 | Enhanced circulation effector composition and method | ALZA CORPORATION (US) | 2006-12-19 | — | — | US | disclosed |
| US-20040247663-A1 | Liposomes with effector biomolecules attached to the distal ends of hydrophilic polymer chains provide increased time in the bloodstream; polymyxin B used for septic shock | ALZA CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-20030198665-A1 | Enhanced circulation effector composition and method | ALZA CORPORATION | 2003-10-23 | — | — | US | disclosed |
| US-6586002-B2 | Slow down of renal clearance by parenterally administering a liposome having an outer layer of polyoxyethylene glycol chains; effectors, e.g., Fab fragments, CD4 glycoproteins, covalently attached to the distal ends of the polymer chain | ALZA CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6326353-B1 | 123THERAPY FOR SEPTIC SHOCK; ADMINISTERING POLYMYXIN BY INJECTION | SEQUUS PHARMACEUTICALS, INC. | 2001-12-04 | — | — | US | disclosed |
| US-20010043929-A1 | Enhanced circulation effector composition and method | ALZA CORPORATION | 2001-11-22 | — | — | US | disclosed |
| US-6180134-B1 | FOR TREATING SUBJECT WITH SMALL EFFECTOR MOLECULES WHICH ARE NORMALLY SUBJECT TO RAPID RENAL CLEARANCE FROM BLOODSTREAM; FOR TREATING SEPTIC SHOCK, FOR USE IN TREATING INFLAMMATION RELATED TO NEUTROPHIL RECRUITMENT AND TISSUE INFILTRATION | SEQUUS PHARMACEUTICALS, INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0689428-B1 | ENHANCED CIRCULATION EFFECTOR COMPOSITION AND METHOD | SEQUUS PHARM INC (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5620689-A | ADMINISTERING A SUSPENSION OF LIPOSOMES HAVING A SURFACE COATING OF POLYETHYLENE GLYCOL CHAINS | SEQUUS PHARMACEUUTICALS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0689428-A1 | ENHANCED CIRCULATION EFFECTOR COMPOSITION AND METHOD | SEQUUS PHARMACEUTICALS, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021235-A1 | ENHANCED CIRCULATION EFFECTOR COMPOSITION AND METHOD | LIPOSOME TECHNOLOGY, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994021281-A1 | POLYMER-POLYPEPTIDE COMPOSITION AND METHOD | LIPOSOME TECHNOLOGY, INC. (US) | 1994-09-29 | — | — | WO | disclosed |